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ProliferationThe only known structural protein required for formation of myelin, produced by oligodendrocytes in the
central nervous system, is myelin basic protein (MBP). This peripheral membrane protein has different
developmentally-regulated isoforms, generated by alternative splicing. The isoforms are targeted to distinct sub-
cellular locations, which is governed by the presence or absence of exon-II, although their functional expression is
often less clear. Here, we investigated the role of exon-II-containingMBP isoforms and their link with cell prolif-
eration. Live-cell imaging and FRAP analysis revealed a dynamic nucleocytoplasmic translocation of the exon-II-
containing postnatal 21.5-kDa MBP isoform upon mitogenic modulation. Its nuclear export was blocked upon
treatment with leptomycin B, an inhibitor of nuclear protein export. Next to the postnatal MBP isoforms, embry-
onic exon-II-containingMBP (e-MBP) is expressed in primary (immature) oligodendrocytes. The e-MBP isoform
is exclusively present in OLN-93 cells, a rat-derived oligodendrocyte progenitor cell line, and interestingly, also in
several non-CNS cell lines. As seen for postnatalMBPs, a similar nucleocytoplasmic translocation uponmitogenic
modulation was observed for e-MBP. Thus, upon serum deprivation, e-MBP was excluded from the nucleus,
whereas re-addition of serum re-established its nuclear localization, with a concomitant increase in proliferation.
Knockdown ofMBP by shRNA conﬁrmed a role for e-MBP in OLN-93 proliferation, whereas the absence of e-MBP
similarly reduced the proliferative capacity of non-CNS cell lines. Thus, exon-II-containing MBP isoforms may
regulate cell proliferation via a mechanism that relies on their dynamic nuclear import and export, which is
not restricted to the oligodendrocyte lineage.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Oligodendrocytes are the myelinating cells of the central nervous
system (CNS) with a distinct and carefully regulated proliferation and
differentiation timeline. During their maturation, they synthesize mye-
lin sheaths, which enwrap axons to provide fast nerve conduction and
to ensure axonal integrity [1]. Myelin membranes contain various mye-
lin speciﬁc proteins of which myelin basic protein (MBP) is the second
most abundant one and, most importantly, the only known structural
protein that is indispensable for CNS myelin formation [2–5].Bromo-2′-deoxy-uridine; CDK,
M1, chromosome region main-
; FGF, ﬁbroblast growth factor;
P, embryonic myelin basic pro-
godendrocyte lineage; HD, high
oclonal antibody; MBP, myelin
s / cytoplasm; N/M, nucleus /




ights reserved.Several MBP isoforms are present in oligodendrocytes and it has
been well established that the MBP family is generated from a large,
11 exon-containing gene complex called Golli (gene in the oligodendro-
cyte lineage). Given the presence of two primary transcription starting
sites, two subfamilies can be distinguished, i.e., classical MBPs,
expressed by myelinating oligodendrocytes, and golli MBPs that are
also expressed bymany other cells [6–9]. From this large gene complex,
the alternative splicing of the seven most downstream exons (denoted
by Roman numerals I–VII) gives rise to a single MBP mRNA transcript
[10], which is transcribed into different classical MBP isoforms, four of
which, i.e., 21.5-, 18.5-, 17-, and 14-kDa, are predominantly expressed
in rats. The 14- and 18.5-kDa isoforms lack exon-II and localize to
compact myelin, whereas the exon-II-containing 17- and 21.5-kDa
MBP isoforms localize predominantly to the nucleus, but also appear
in the cytoplasm [11–13]. These classical postnatal MBP isoforms are
synthesized in a developmentally-regulated manner. Thus, exon-II-
positiveMBP isoforms are expressed during early stages ofmyelination,
whereas the expression of exon-II-negative MBP isoforms peaks in late
myelination [14–16]. Interestingly, in addition to the classicalMBPpost-
natal isoforms, embryonic isoforms also exist [17–18], including an
exon-II-containing 16-kDa MBP isoform, the expression of which
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which expression is not limited to the oligodendrocyte lineage [17].
Thus far, MBP-related research has largely focused on exon-II-
negative MBP isoforms, whereas knowledge of the function of nuclear
exon-II-positive MBP isoforms is rather scanty. Speciﬁcally, exon-II-
negative isoforms play a role in myelin compaction, and also serve as
‘molecular sieves’ by selectively allowing access of only proteins with
short cytoplasmic tails into myelin membranes [2,19–21]. In addition,
these isoforms act in signaling, cytoskeleton polymerization and stabili-
zation, and calcium–calmodulin binding [2,22–25]. In contrast, the
exon-II-containing isoforms localize to the nucleus and cytoplasm
when expressed in HeLa cells and oligodendrocytes [12,13], but the
functional consequences of this distinct subcellular localization are
still unresolved. However, as observed for other nuclear proteins, the lo-
calization of exon-II-containingMBP is affected by cell–cell contact [12],
whereas nuclear translocation appears to be an active process, which is
time, energy, and temperature dependent [12,26]. In terms of function-
ing, it is known that the 21.5-kDaMBP exon-II-containing isoform plays
a role in calcium homeostasis in oligodendrocytes [23]. In addition, via
the induction of a diffusible factor, 21.5-kDaMBPpromotes proliferation
of the immortalized N19-oligodendrocyte cell line, and enhances
neurite outgrowth [27].
Here, we have investigated the role of the subcellular localization of
postnatal and embryonic exon-II-positive MBP isoforms and their link
with proliferation. Photobleaching (FRAP) and live-cell imaging tech-
niques demonstrated a dynamic nucleocytoplasmic translocation of
postnatal exon-II-containing 21.5-kDaMBP–RFPuponmitogenicmodu-
lation. Our ﬁndings further revealed that a 16-kDa exon-II-containing
embryonicMBP isoform (e-MBP) is expressed inmany cell lines, includ-
ing non-myelinating cell lines, and like the postnatal 21.5-kDaMBP iso-
form, is involved in cell proliferation. Therefore, exon-II-containingMBP
isoforms play a speciﬁc regulatory role not only in the early regulation of
themyelinmachinery, but in amore general context, also in (embryon-
ic) cell proliferation.
2. Materials and methods
2.1. Cell culture
2.1.1. Primary oligodendrocytes
Primary oligodendrocyte cultures were generated from 1 to 3 day
old Wistar rats as described [28]. Brieﬂy, rats were decapitated, fore-
brains were collected, and a single cell suspension was obtained byme-
chanical and enzymatic (papain) digestion. Cells were cultured in
DMEM (Gibco, Invitrogen, Paisley, Scotland) supplemented with 10%
fetal calf serum (FCS, not heat-inactivated, Bodinco, Alkmaar, The
Netherlands), L-glutamine (Invitrogen) and penicillin/streptomycin
(P/S, Invitrogen) for 10–14 days on poly-L-lysine (PLL, 5 μg/mL, Sigma,
St. Louis, MO)-coated tissue culture ﬂasks (Nunc, Roskilde, Denmark).
Oligodendrocyte progenitor cells (OPCs), growing on top of an astrocyte
monolayer, were then isolated by a shake-off procedure, followed by
differential adhesion. After shaking, OPCswere collected from themedi-
um and for Western blot analysis plated on PLL-coated 10-cm dishes
(Nunc, Naperville, IL) at a cell density of 106 cells/dish. The OPCs
were cultured in SATO medium [28], containing PDGF-AA (10 ng/mL,
Peprotech, Rocky Hill, NJ) and FGF-2 (10 ng/mL, Peprotech) for
2 days. Differentiation was induced by growth factor withdrawal
and cells were allowed to differentiate for 3, 7, and 10 days in SATOme-
dium supplemented with 0.5% FCS. Medium was refreshed twice a
week.
2.1.2. Cell lines
The oligodendrocyte progenitor cell line OLN-93, a kind gift from
Dr. Christiane Richter-Landsberg [29], was cultured in DMEM supple-
mented with L-glutamine, P/S and 10% FCS (heat-inactivated) under
standard incubation conditions (humidiﬁed atmosphere, 7.5% CO2,37 °C). Experiments were performed at passage 25–36. For carrying
out a proliferation assay and immunocytochemical analysis, the cells
were cultured on 8-well chamber slides (Nunc), pre-coated with PLL
at the indicated cell densities for 3 days. Cells were cultured in 10%
FCS unless otherwise indicated. After 2 days in culture, cells were treat-
ed with 20 μM roscovitine (Sigma) or leptomycin B (LMB, 10 ng/mL, LC
Laboratories, Woburn, MA) for 24 and 6 h, respectively. For Western
blot analysis, cells were plated on PLL-coated 10-cm tissue culture
dishes (Corning Costar, Lowell, MA). Cell densities were calculated
according to the corresponding surface area of 8-well chambers. For
ﬂuorescence recovery after photobleaching (FRAP) and live-cell imag-
ing, OLN-93 cells were plated on PLL-coated 2-well Labtek-II chambered
coverglass (Nunc, 50,000 cells/well). After 24 h, cells were transfected
with 21.5-kDaMBP–RFP [25] or RFP, using Lipofectamine™ 2000 Trans-
fection Reagent (Invitrogen) as described in themanufacturer's instruc-
tions. Experiments were performed 24 h after transfection. HEK293,
HeLa, and HepG2 cells were cultured as OLN-93 cells. For BrdU assays
and e-MBP immunocytochemistry, cells were plated a day prior to the
analyses on 13-mm glass cover slides in 24 well plates at a cell density
of 25,000 (HeLa, HepG2) or 35,000 (HEK293) per well.
2.2. Rat brain tissue
Brain tissue of Wistar rats was homogenized, using a Wheaton ho-
mogenizer, in 1 mL of ice-cold TE buffer (10 mM Tris–HCl, 2 mM
EDTA, 0.25 M sucrose) and a cocktail of protease inhibitors (Complete
Mini, Roche Diagnostics, Mannheim, Germany). Samples were stored
at−80 °C until further biochemical analysis.
2.3. Constructs and lentiviral transduction
The generation of the plasmid coding for 21.5-kDa MBP–RFP has
been described previously (pERFP-C1-rmMBP-21.5-UTR [23]). The plas-
mid coding for RFP was pERFP-C1. Lentiviral-mediated knockdown of
gene expression was performed using the pHR′trip-PGK-eGFP-WPRE-
H1 vector. For this purpose, the vector was modiﬁed to allow for inser-
tion of different short hairpins. In short, the pHR′trip-PGK-eGFP-WPRE-
H1 vector was ampliﬁed with two opposing primers containing either
the recognition sequence for AscI (5′-CGTGGCGCGCCATCTGTGGTCTC
ATACAGAACTT-3′) or SbfI (5′-CGTCCTGCAGGGGAAAAGCTTATGAATTC
GGC-3′) and self-ligated (restriction sites underlined). The PCR ampliﬁ-
cation was performed using Pfu turbo DNA polymerase (Stratagene, La
Jolla, CA). Short hairpin sequences cloned into the modiﬁed vector had
the following topology: 5′-acaaGGCGCGCC(N19-23)actcgaga(N19-
23c)gtttttCCTGCAGGacaa-3′ (AscI and SbfI restriction sites in capital
letters). Ordered DNA oligonucleotides (Biolegio, Nijmegen, The
Netherlands) were primed with a reverse primer (5′-TTGTGCCTGC
AGGAAAAA-3′) and ﬁlled in using Phi29 DNA polymerase (New En-
gland Biolabs, Beverly, MA). Ligation was performed using 1 μL of
hairpin DNA and 150 ng of digested modiﬁed pHR′trip-PGK-eGFP-
WPRE-H1. The target sequence for MBP, directed against the inter-
face of exon-III and exon-IV, was: 5′-acaaaGGCGCGCCA GCAGAGGA
CCCAAGATGAAACTCGAGATTCATCTTGGGTCCTCTGCGTTTTTCCTGCA
GGcacaa-3′. Lentiviral particles were produced as described [30].
Cells were exposed to two times diluted lentiviruses containing
MBP shRNA, for 16 h in the presence of 4 μg/mL hexadimethrine bro-
mide (polybrene; Sigma). Concomitant expression of GFP conﬁrmed
shRNA transduction. Analyses were performed 10–15 days after
transduction.
2.4. RT-PCR
Total RNA was isolated on day 3 using the InviTrap Spin Cell RNA
Mini Kit (Invitek, Stratec, Berlin, Germany). The RNA yield and purity
were quantiﬁed spectrophotometrically by measuring A260 and A280
absorbances in a Nano-Drop ND-Spectrophotometer (V3.1.0, Thermo
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performed in the presence of oligo(dT) 12–18 and dNTPs (Gibco) with
superscript II reverse transcriptase (Roche Diagnostic, Almere,
Netherlands) according to the manufacturer's instructions. From total
cDNA, the embryonic DNA band was generated by using a forward
primer against embryonic exon [17], 5′-GGGAGGACAACACCTTCAAA-
3′ and a reverse primer against MBP–exon-II, 5′-GGCATGAGAAGGCA
GAGG-3′. Primers were designed and purchased from Biolegio
(Nijmegen, The Netherlands). The reaction conditions were 1 cycle of
5 min at 94 °C, followed by 55 cycles of 30 s at 94 °C, 30 s at 55 °C,
1 min at 72 °C, and 1 cycle of 7 min at 72 °C. The samples were run
on a 2% agarose gel.
2.5. Subcellular fractionation
After three washes with phosphate-buffered saline (PBS), cells were
scraped in 500 μL subcellular fractionation buffer (250 mM sucrose,
20 nM HEPES pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT and protease inhibitor cocktail), and collected in a
1.5-mL Eppendorf tube. The lysates were passed 20 times through a
25G needle, using a 1-mL syringe, and cooled for 20 min on ice. The nu-
clear fraction was pelleted at 720 g for 5 min at 4 °C. The supernatant
was collected. The nuclear pellet was dissolved in 500 μL fractionation
buffer, dispersedwith a pipette, and passed 10 times through a 25Gnee-
dle, and centrifuged at 720 g for 10 min. The supernatant was collected
and the nuclear pellet was washed 5 times with fractionation buffer. In
parallel, to separate the membrane fraction (pellet) from the cytoplas-
mic fraction (supernatant), the collected supernatants were centrifuged
at 10,000 g for 30 min at 4 °C. The cytoplasmic fractionwas precipitated
with trichloroacetic acid [31]. The nuclear, membrane, and cytoplasmic
pellets were dissolved in equal amounts of TNE lysis buffer (50 mM
Tris–HCl, 5 mM EDTA, 150 mM NaCl, 1% Triton X-100, and protease
inhibitor cocktail), and subjected to Western blot analysis.
2.6. Immunocytochemistry
Cells were ﬁxedwith 2% paraformaldehyde (PFA, Merck) for 15 min
at room temperature (RT) followed by incubation for 15 min with 4%
PFA at RT. Cells were washed three times with PBS, and blocked and
permeabilized with 0.1% Triton X-100 in 4% bovine serum albumin
(BSA) for 30 min at RT. Cells were incubated with primary antibodies
diluted in 4% BSA for 1 h at RT. Primary antibodies were monoclonal
rat anti-MBP antibody (1:10, Millipore, Billerica, MA), and polyclonal
anti-GFP (1:00, Molecular Probes, Invitrogen). After washing three
times with PBS, cells were incubated with Alexa- (1:500, Invitrogen)
or Cy3- (1:400, Jackson ImmunoResearch, West Baltimore Pike, PA)
conjugated secondary antibodies diluted in 4% BSA for 30 min at RT,
followed by washing three times with PBS. During incubation with the
secondary antibody, DRAQ5™ (1:500, Bistatus Limited, Leicestershire,
UK) was also included to visualize the nuclei. Cells were mounted in
DAKOmounting medium. Images were acquired by confocal microsco-
py, using a Leica SP2 AOBS CLSM (Leica Microsystems, Heidelberg,
Germany) equipped with an argon laser (488 nm), 2 He/Ne lasers
(543 and 633 nm, respectively) and with Leica confocal software. A
63×/1.25 oil immersion objective was used for 2-channel scanning.
The Cy3/Alexa 546 and Alexa 633 signals were recorded sequentially
in the green and red channels, respectively. The percentage of cells
that expressed MBP in their nucleus was quantiﬁed by determining
the ratio of cells with nuclear MBP over the total cell number. At least
10 ﬁelds, each containing more than 30 cells, were counted in three
independent experiments.
2.7. BrdU incorporation assay
Cell proliferation was determined by a 5-Bromo-2′-deoxy-uridine
(BrdU)-incorporation assay (Roche), according to the manufacturer'sinstructions with slight modiﬁcations. Three days after plating, cells
were incubated with 10 μM BrdU for 8 h (OLN-93) or 16 h (HEK293,
HeLa) at 37 °C prior to ﬁxation. The cells were washed three times
with PBS and ﬁxed with ice cold 95% ethanol–5% acetic acid for
15 min at RT. Subsequently, the cells were incubated with mouse
monoclonal IgG antibody against BrdU (1:15) in a humidiﬁed chamber
for 30 min at 37 °C, followed by three washes with PBS and an incuba-
tion with secondary antibody, anti-mouse Ig-ﬂuorescein (1:15) for
30 min at 37 °C. During incubation with the secondary antibody,
DRAQ5™ was also included to stain the nuclei. After washing three
times with PBS, cells were examined by ﬂuorescencemicroscopy as de-
scribed above. The percentage of proliferating cells was quantiﬁed by
determining the ratio of BrdU-positive cells over DRAQ5™- or GFP-
positive cells. When the proliferation assay was carried out on the
same sample as e-MBP immunocytochemistry, the cells were ﬁrst sub-
jected to e-MBP-immunocytochemistry (see above). The percentage of
proliferating cells that express e-MBP in the nucleus was quantiﬁed by
determining the ratio of cells with nuclear e-MBP over the total number
of proliferating cells. At least 10 ﬁelds, each containing more than 40
cells, were counted in three independent experiments.
2.8. Live-cell imaging
At 24 h after transfection, cells were subjected to live-cell imaging
for 3 or 6 h at 37 °C under an atmosphere of 5% CO2. All measurements
were done in the presence of cycloheximide (50 μg/mL, Sigma), which
was added 1 h before the onset of the experiment. The Z-stacks with
0.5 μm optical serial sections were acquired every 10 min using a Spin-
ning Disk Leica DM IRE2 confocal laser scanning microscope (Leica
Microsystems, Heidelberg, Germany), equippedwith a 63×/1.3 glycerol
immersion objective, and Argon (457 nm, 476 nm, 488 nm, 514 nm),
and Krypton (568 nm, 647 nm) lasers. Under these conditions, and
given the low laser power used, bleaching hardly occurred, if at all. Im-
ages were recorded with a Stanford Photonics XR/Mega-10I (intensi-
ﬁed)-CCD camera using intuitive InVivo (Media Cybernetics) software
with imaging format 1024 × 1024 pixels. In order to avoid any move-
ment of the cell in the z direction, the z-stacks were merged to one
picture using Imaris (Bitplane AG, Switzerland).
2.9. FRAP analysis
At 24 h after transfection, the cells were subjected to FRAP analysis
as described in [32] using a Zeiss 780NLO confocal laser scanningmicro-
scope (Carl Zeiss MicroImaging GmbH, Jena, Germany), equipped with
a 63×/1.3 glycerol immersion objective in an acquisition mode
256 × 256 frame size, 2.55-μs pixel dwell time, 390.98-ms scan time
without averaging. Brieﬂy, 10 pre-bleach images were taken. Bleaching
was performed with a DPSS-laser (561 nm) at 100% laser power. To
monitor nuclear import, the entire nucleus was bleached, whereas for
determination of nuclear export, the cytoplasm was bleached. For
bleaching of the nucleus, 13 iterations with 100.85-μs pixel dwell
time, and for bleaching the cytoplasm, 6 iterations for MBP–RFP and 9
iterations for RFP with 50.85-μs pixel dwell time were used, resulting
in 90% bleaching of the nucleus and 70–80% bleaching of the cytoplasm.
Post-bleach images were taken in 4 sets. The ﬁrst set consisted of 30
frames, taken at an interval of 0.4 s (fastest); the second of 30 frames
with 1.2-s intervals, the third of 30 frames at 5-s time intervals, and
the remainder was taken at 10-s intervals. The images were acquired
at 1% laser power. Importantly, upon continuous bleaching of dye-
loaded plastic at one particular region, our system bleached up to a
depth of 9 μm in the z direction (data not shown). Accordingly, since
OLN-93 cells form a layerwith a thickness of 5 μm, our system is capable
of readily bleaching the entire nucleus or cytoplasm. The ﬂuorescence
intensities of the bleached area (nucleus or cytoplasm) and non-
bleached area (cytoplasm or nucleus) were analyzed by ZEN software
(Zeiss). In addition, an area where no cells were present was recorded,
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was very low, however for the accuracy of our calculations, the signal
was subtracted from the ﬂuorescence intensities of the bleached and
non-bleached areas. For determination of the nuclear import rate, the
ratio of ﬂuorescence intensity of nucleus to cytoplasm was calculated.
The pre-bleach ratio was set to 100%, and the other values were calcu-
lated accordingly. For determining the nuclear export rate, the ratio of
ﬂuorescence intensity of cytoplasm to nucleus was calculated. Import
rates of 1500 s for 21.5-kDa MBP–RFP and 600 s for RFP, and export
rates of 1400 s for 21.5-kDaMBP–RFP and 600 s for RFP were analyzed,
using a one-phase association curve in GraphPad Prism 5. To compare
the rates at the different conditions, half-lives were plotted separately
and compared, using a one way ANOVA followed by a Newman–Keuls
posttest.
2.10. Western blot analysis
Cells were scraped in PBS and centrifuged at 9000 g for 10 min at RT.
Cell pellets were lysed in TNE-lysis buffer. Protein concentrations were
determined by a BioRad DC protein assay (Bio-Rad Laboratories, Hercu-
les, CA), using BSA as standard. For the total cell lysate, equal amounts of
protein (total cell lysates) or volume (subcellular fractionation) were
mixed with reducing sample buffer, heated for 5 min at 95 °C, and ap-
plied onto 15% SDS-polyacrylamide gels. Proteins were transferred to
a nitrocellulose membrane using a wet blotting system (Bio-Rad). The
membranes were rinsed with PBS and incubated for 1 h in blocking
buffer (Odyssey blocking buffer (Li-Cor Biosciences, Lincoln, NE), dilut-
ed with an equal volume of PBS) at RT. After blocking, the membranes
were incubated overnight with primary antibodies diluted in blocking
buffer containing 0.1% Tween-20. Primary antibodies used were mono-
clonal rat anti-MBP (1:100), polyclonal rabbit anti-MBP (1:1000,
Dakocytomation, Carpinteria, CA), polyclonal guinea pig anti-exon-II
(1:1000, a kind gift from Dr. Liliana Pedraza, Montréal, Canada [12]),
monoclonal mouse anti-histone H3 antibody (Abcam, Cambridge, UK),
monoclonal anti-mouse NCAM 140/180 (Sigma), and monoclonal
mouse anti-β-actin (1:1000, Sigma) diluted in blocking buffer. The
membranes probed with polyclonal guinea pig anti-exon-II were incu-
bated next with a goat anti-guinea pig IgG linker antibody (1:1000,
Jackson ImmunoResearch). The membranes were washed three times
with PBS containing 0.05% Tween-20 (PBS-T) and incubated for 1 h
with appropriate IRDye-conjugated secondary antibodies (Li-Cor
Biosciences) at RT. After incubation, membranes were washed three
times with PBS-T. Signals were detected using the Odyssey Infrared Im-
aging System (Li-Cor Biosciences). The protein bands were quantiﬁed
by the imaging software ImageJ.
2.11. Statistics
Data (mean ± standard deviation (SD)) for both immunocyto-
chemistry and Western blots were analyzed from at least three
independent experiments. Statistical signiﬁcance was calculated by
Student's t-test for comparison between two means and by one-way
ANOVA followed by Newman–Keuls posttest to compare more than
two means in GraphPad Prism 5. p-Values b0.05, b0.01, and b0.001
are considered statistically signiﬁcant (*, **, and ***, respectively).
3. Results
3.1. The localization of 21.5-kDa MBP in OLN-93 cells changes upon
mitogenic modulation
To investigate the potential role of nucleus-localized exon-II-
containing MBP isoforms as mitogenic modulators, we employed an
oligodendrocyte-derived cell line, OLN-93. These cells represent an
established model for the oligodendrocyte progenitor cells, and impor-
tantly, like many other oligodendroglial cell lines, they do not expresspostnatal classical MBP isoforms [23,29]. Therefore, OLN-93 cells may
serve as a convenient model to study the function of exon-II-positive
MBP isoforms without potential interference of exon-II-negative MBP
isoforms, as their presence downregulates the expression of exon-II-
containing MBP isoforms.
To assess whether 21.5-kDa MBP regulates proliferation in OLN-93
cells, we transfected the cells with RFP-tagged 21.5-kDa MBP and RFP
alone, and subsequently examined their proliferation with a BrdU-
incorporation assay. Transfection with 21.5-kDa MBP–RFP signiﬁcantly
increased total OLN-93 proliferation as compared to RFP-transfected
cells (Fig. 1A, B). Remarkably, not only the proliferation of the
transfected cells was increased, but also the proliferation of the cells
that did not express 21.5-kDa MBP (Fig. 1A), suggesting that a secreted
diffusible factor might modulate proliferation, as has been suggested
recently [27].
To determinewhether the known distinct cytoplasmic versus nucle-
ar localization of 21.5-kDa MBP, and hence nucleocytoplasmic translo-
cation, might be linked to proliferation, we next examined the
intracellular localization of 21.5-kDaMBP–RFP uponmitogenicmodula-
tion. When cultured in 10% FCS-containing medium, i.e., a condition
where cells are highly proliferative, theOLN-93 cells displayed a primar-
ily nuclear localization of the 21.5-kDaMBP–RFP (Fig. 1C, D). In contrast,
upon serum deprivation, i.e., a condition that inhibits proliferation, the
nuclear localization of 21.5-kDa MBP–RFP decreased by approx. 30%.
However, re-addition of serum at least partially re-established the nu-
clear localization of the 21.5-kDa isoform (SF + Recovery; Fig. 1C, D).
Interestingly, upon treatmentwith leptomycin B (LMB), anunsaturated,
branched-chain fatty acid that blocks nuclear export of many proteins
[33,34], the 21.5-kDa MBP–RFP remained trapped in the nucleus at
serum-free conditions (SF + LMB; Fig. 1C, D).
To examine in further detail whether a regulated nucleocytoplasmic
translocation uponmitogenicmodulation relies upon active shuttling of
theMBP-isoform between the nucleus and cytoplasm, we exploited the
ﬂuorescence properties of the RFP-labeled 21.5-kDa isoform. As
revealed by live-cell imaging, when 24 h after transfection MBP–RFP
labeled cells were subsequently cultured in serum-free medium, the la-
beled protein rapidly disappeared from the nucleus within a time inter-
val of approx. 2 h, after which the process further proceeded until
nuclear localization could be barely detected after 6 h (cf., Fig. 1E, 10%
FCS versus SF). However, when LMB was included into the serum-free
medium, nuclear export of 21.5-kDa MBP–RFP was effectively
prevented (Fig. 1E, SF + LMB). Re-addition of serum-containing
media to the cells at either condition, which re-established the pro-
liferative state of the cells, simultaneously led to a relatively fast
‘recovery’ of nucleus-localized MBP–RFP, which occurred as fast as
within approx. 30 min after addition of serum-containing medium
(Fig. 1E, SF + Recovery). To exclude de novo synthesis of trans-
porters and MBP under the various conditions, all the experiments
were performed in the presence of the protein synthesis inhibitor
cycloheximide. Importantly, the nucleocytoplasmic shuttling of
21.5-kDa MBP–RFP was not an RFP-induced artifact, as the localiza-
tion behavior of RFP alone was not altered upon mitogenic modula-
tion (Supplementary Fig. 1). In this context, it is also relevant to
note that RFP is considered the most appropriate control, since
exon-II-negative MBP isoforms will not enter the nucleus. Hence,
our ﬁndings indicate that the postnatal 21.5-kDa exon-II containing
MBP isoform displays a considerable dynamics as reﬂected by its
exit and entry into the nucleus, thereby closely correlating with
cell proliferation of OLN-93 cells.
3.2. 21.5-kDa MBP actively shuttles in OLN-93 cells between the nucleus
and cytoplasm upon mitogenic modulation
To more precisely determine the dynamics and nuclear export and
import rates of the exon-II-containing 21.5-kDa MBP–RFP in live cells,
we next performed photobleaching experiments (FRAP) under similar
Fig. 1. The localization of 21.5-kDa MBP–RFP changes upon mitogenic modulation. OLN-93 cells were transiently transfected with 21.5-kDa MBP–RFP or RFP and treated as
indicated. (A, B) At 24 h after transfection, cell proliferation was determined using a BrdU incorporation assay. The percentage of proliferative cells, i.e., BrdU-positive, of
total, i.e., DRAQ5-positive cells was determined. Scale bar is 25 μM. Note that transfection with 21.5-kDa MBP–RFP signiﬁcantly increases proliferation as compared to transfection
with RFP alone (t-test, *p b 0.05). (C, D) Cells were either ﬁxed 24 h after transfection (10% FCS), or cultured in serum-free medium in the absence (SF) or presence of 10 ng/mL
leptomycin B (SF + LMB). After 6 h, cells were ﬁxed or allowed to recover in normal culture medium supplemented with 20% FCS (SF + Recovery) for 3 h. Localization of 21.5-kDa
MBP–RFP at the indicated condition is shown in panel C. Given the low transfection efﬁciency, representative single cells of 3 independent experiments are shown. Scale bar is 20 μm.
At the indicated conditions, the percentage of cells with nuclear 21.5-kDa MBP–RFP expression, relative to the total, DRAQ5-positive cells was examined (panel D). Note that upon inhi-
bition of cell proliferation, 21.5-kDaMBP–RFP preferentially localizes to the cytoplasm in the absence of LMB, but not in the presenceof LMB,whereas in control and during recovery, i.e., at
proliferating conditions, 21.5-kDa MBP–RFP shows a more pronounced nuclear localization. The graphs were plotted as mean + SD and statistical analysis was performed by GraphPad
Prism 5 (one-way ANOVA followed by the Newman–Keuls posttest; *p b 0.05). (E) 24 h after transfection, the localization of 21.5-kDaMBP–RFP was recorded in live cells for 6 h in 10%
FCS, and in serum-free medium in the absence (SF) or presence of 10 ng/mL leptomycin B (SF + LMB). Alternatively, cells were kept for 6 h in serum-free medium, after which the cell
imageswere recorded for 3 h inmedium supplementedwith 20% (SF + Recovery). Z-stacks with 0.5 μmoptical sections were acquired every 10 min. 3D image analysis was performed
by IMARIS software. All measurements were performed in the presence of 50 μg/mL cycloheximide to inhibit de novo protein synthesis. Scale bar is 10 μm. Note that 21.5-kDaMBP–RFP
remained in the nucleus inmedium containing 10% FCS, whereas in serum-free medium 21.5-kDaMBP–RFP translocates to the cytoplasm in the absence, but not in the presence of LMB.
During recovery, 21.5-kDa MBP–RFP translocates to the nucleus.
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Fig. 2.Nuclear import rate of 21.5-kDaMBP–RFP changes uponmitogenicmodulation. (A)OLN-93 cellswere transiently transfectedwith 21.5-kDaMBP–RFP or RFP (control). At 24 h after
transfection, cells were subjected to FRAP analysis in 10% FCS, or prior to FRAP analysis pretreated with serum-free medium for 6 h (SF), or allowed to recover from incubation for 6 h in
serum-freemedium (3 h in20% FCS, SF + Recovery). Representative confocal images of cells positive for 21.5-kDaMBP–RFP, before and after bleaching of the nucleus at all conditions, are
shown. Imageswere acquiredwith 1% laser power, and during bleaching 100% laser power was used. Scale bar is 10 μm. (B–D) Quantitative analysis of the nuclear import rate of (A). The
ratio of ﬂuorescence intensities of nucleus to cytoplasm (N/C) was set to 100% (after subtraction of background) and the ratio after bleaching was calculated accordingly. The results are
plotted on the graph and ﬁtted with a one-phase association curve using GraphPad Prism 5 (B). The half-life was calculated for each condition over a 1500-s time period for the 21.5-kDa
MBP–RFP (C), and for 600 s for the RFP (D). Note that the nuclear import rate was signiﬁcantly lower in serum-free medium and signiﬁcantly higher during recovery, when compared to
the rate obtained in the presence of 10% FCS for 21.5-kDaMBP–RFP (but not for RFP). For each condition, 8–10 cells weremeasured at once and this procedure was repeated at least three
times. The graphs were plotted as mean + SD and statistical analysis was performed using GraphPad Prism 5 (one-way ANOVA followed by the Newman–Keuls posttest **p b 0.01).
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technique to study the dynamic behavior of proteins, while it provides
detailed insight into the kinetics of the protein of interest [35–38]. To
measure nuclear import rates, the 21.5-kDa MBP–RFP-ﬂuorescence,
present in the nucleus, was bleached up to 90% (Fig. 2A), and the
rate of the recovery of ﬂuorescence intensity was recorded for up to
1500 s, i.e., when it reached its equilibrium. Compared to othernucleocytoplasmic shuttling proteins, the ﬂuorescence recovery rate of
21.5-kDa MBP–RFP was relatively slow as compared to β-catenin, Lgs,
and VDBRB1 [38–40], but similar to STAT3 [36]. Fluorescence recovery
in the nucleus was calculated and shown as the nuclear to cytoplasmic
ratio (N/C ratio) in one-phase association curves (Fig. 2B). Interestingly,
the nuclear import rate of MBP–RFP, as reﬂected by its shorter half-life,
was signiﬁcantly faster in medium containing 10% FCS than in serum-
Fig. 3.Nuclear export rate of 21.5-kDaMBP–RFP changes uponmitogenicmodulation. (A) OLN-93 cellswere transiently transfectedwith 21.5-kDaMBP–RFP or RFP (control). At 24 h after
transfection, cells were subjected to FRAP analysis in 10% FCS, or prior to FRAP analysis pretreated with serum-free medium for 6 h in the absence (SF) or presence of leptomycin B
(SF + LMB), or allowed to recover from incubation for 6 h in serum-free medium (3 h in 20% FCS, SF + Recovery). Representative confocal images of cells positive for 21.5-kDa
MBP–RFP before and after bleaching of the cytoplasm at all conditions are shown. Images were acquired with 1% laser power, and during bleaching 100% laser power was used. Scale
bar is 10 μm. (B–D) Quantitative analysis of the nuclear export rate of (A). The ratio of ﬂuorescence intensities of cytoplasm to nucleus (C/N) was set to 100% (after subtraction of back-
ground) and the ratio after bleaching was calculated accordingly. The results are plotted on the graph and ﬁttedwith a one-phase association curve using GraphPad Prism 5 (B). The half-
life was calculated for each condition over a 1500-s time period for the 21.5-kDa MBP–RFP (C), and for 600 s for the RFP (D). Note that the nuclear export rate is signiﬁcantly higher in
serum-free medium, when compared to the rate obtained in the presence of 10% FCS for 21.5-kDaMBP–RFP (but not for RFP). For each condition, 8–10 cells were measured at once, and
this procedure was repeated at least 3 times. The graphs were plotted as mean + SD and statistical analysis was performed using GraphPad Prism 5 (one-way ANOVA followed by the
Newman–Keuls posttest *p b 0.05, **p b 0.01).
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upon re-addition of 10% FCS to a rate similar to that as determined be-
fore serum-depletion (Recovery). Notably, mitogenic modulation did
not affect the nuclear import rate of RFP (Fig. 2D, Supplementary Fig. 2).Next, we determined the nuclear export kinetics of 21.5-kDa
MBP–RFP upon mitogenic modulation. For that purpose, the 21.5-kDa
MBP–RFP ﬂuorescence of the cytoplasm was bleached up to 70–80%
(Fig. 3A). As for determination of the import rates, the ﬂuorescence
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was monitored until it reached equilibrium after approx. 1400 s
(Fig. 3B). Like the nuclear import rate, the nuclear export rate was
slower, when compared to other proteins mentioned above [38–40],
but also proteins such as STAT3 with similar export rates have been re-
ported [36]. Analysis of the half-lives revealed that the nuclear export
rate of 21.5-kDa MBP–RFP was signiﬁcantly slower in 10% FCS than in
serum-free conditions. However, when OLN-93 cells were simulta-
neously treated with LMB, thereby inhibiting CRM1-dependent nuclear
protein export, the nuclear export rate became substantially slower as
reﬂected by a longer half-life, conﬁrming the live-cell imaging results,
and further suggesting that the nuclear export of 21.5-kDa MBP–RFP
is nuclear export signal (NES)-dependent. Surprisingly, the nuclear ex-
port rate of 21.5-kDa MBP–RFP, 3 h after mitogenic recovery, was not
decreased, given a short half-life value comparable to the half-life of
21.5-kDa MBP–RFP in serum-free medium. This result may suggest
that additional factors, such as post-translational modiﬁcation or
other proteins, might regulate MBP nuclear export. As for nuclear im-
port, FRAP analysis for RFP revealed that the nuclear export rates of
RFP were not dependent on mitogenic modulation (Fig. 3D, Supple-
mentary Fig. 3), indicating MBP speciﬁcity. Importantly, these ﬁndings
show in addition that at 10% FCS, i.e., in mitogenic conditions, the im-
port rate of 21.5-kDa MBP–RFP exceeds the rate of export (300 s vs.
600 s respectively), meaning that 21.5-kDa MBP–RFP will be located
in the nucleus at cell proliferation. Hence, FRAP analysis supports active
shuttling of 21.5-kDa MBP–RFP between the nucleus and cytoplasm in
OLN-93 cells upon mitogenic modulation. As noted above, OLN-93
cells do not express postnatal MBP isoforms, but it has been suggested
that there is an embryonic MBP isoform, which is expressed prior toFig. 4.OLN-93 cells express 16-kDa e-MBP, localizing in thenucleus and cytoplasm. (A) Equal am
brain (M, 7 μg)were subjected toWestern blot analysis. The expression ofMBPwas visualizedu
antibodies), and a polyclonal antibody directed against MBP-speciﬁc exon-II [12]. Note that th
16 kDa (arrow), whereas the classical MBP isoforms present in myelin appear at 14, 17, 18.5, a
(arrowhead). (B) Total RNA was isolated from OLN-93 cells and RT-PCR was performed usin
and reverse primer against exon-II. The “L” designates the kb ladder. (C) Equal amounts of pro
lysateswere subjected toWestern blot analysis. The expression ofMBPwas characterized using
(polyclonal). The expression of MBP isoforms is compared to the isoform present in OLN-93
expressed at embryonic day 18 (arrow). (D) Primary rat oligodendrocytes were collected at the
jected to Western blot analysis for MBP expression. Note that the 16-kDaMBP isoform (arrow)
however, it is more enriched during early differentiation, i.e., 3 days after initiating differentiati
blots in (A) are shown at a lower intensity as in (C) and (D). (E) OLN-93 cells, 3 days in cultur
image of three independent experiments is shown. Note that MBP localizes both to the nucleuthe expression of postnatal MBP isoforms [29]. Given the mitogenic
modulation of cells by an exon-II driven shuttling of MBP, it was there-
fore of particular interest to subsequently examinewhether this embry-
onic MBP isoform harbors exon-II, and may similarly act as a regulator
of cell proliferation.
3.3. OLN-93 cells express embryonic exon-II containing MBP, localizing in
the nucleus and cytoplasm
As shown in Fig. 4 (arrows), using a monoclonal and polyclonal an-
tibody that both recognize all MBP isoforms, OLN-93 cells abundantly
express an MBP isoform with an apparent molecular mass of 16 kDa.
This isoform did not correspond to any of the classical postnatal MBP
isoforms, i.e., 21.5-, 18.5-, 17- and 14-kDa, which were visualized on
the same immunoblot using myelin extracts of adult brain. In addition,
a weak immunoreactive band was detected at approx. 13 kDa (Fig. 4A,
arrowhead). Western blot analysis with an antibody directed against
MBP–exon-II [12] revealed that both 16- and 13-kDa MBP isoforms in
OLN-93 cells are reactive, indicating that these isoforms contain exon-
II (Fig. 4A). The anti-exon-II antibody only recognizes the exon-II-
containing MBP isoforms in rat myelin (17- and 21.5-kDa), conﬁrming
its speciﬁcity. Thus far, an exon-II-containing 13-kDa MBP isoform has
not been described. Interestingly, an isoform with a molecular mass of
16 kDa has been detected during mouse and rat CNS development,
and was identiﬁed as an embryonic MBP (e-MBP) isoform [16,17,41].
To verify whether the 16-kDa MBP isoform in OLN-93 cells has an
embryonic origin, we next analyzed the expression of e-MBP at the
mRNA level. Using a primer set that recognizes the embryonic exon
[17] and exon-II, RT-PCR analysis revealed the presence of e-MBPounts of protein of total cell lysates of OLN-93 (OLN, 50 μg) andmyelin extracts of adult rat
sing twodifferent antibodies directed against allMBP isoforms (monoclonal and polyclonal
e molecular mass of the most prominent MBP isoform present in OLN-93 cells is around
nd 21.5 kDa. In addition, an exon-II-reactive band at 13 kDa was present in OLN-93 cells
g a speciﬁc set of primers to detect e-MBP, i.e., forward primer against embryonic exon
tein (20 μg), obtained from the indicated embryonic (E) and postnatal (P) total rat brain
two different anti-MBP antibodies, i.e., directed against exon-II or against all MBP isoforms
cells (50 μg). Note that the 16-kDa MBP isoform present in OLN-93 cells is abundantly
indicated days after initiating differentiation. Equal amounts of protein (20 μg) were sub-
is expressed by cultured oligodendrocytes even at 10 days after initiating differentiation;
on. Notably, given the abundant presence of exon-II-negative MBP isoforms inmyelin, the
e, were ﬁxed and stained with anti-MBP monoclonal antibody. A representative confocal
s (bright ﬂuorescence) and to the cytoplasm (punctate appearance). Scale bar is 20 μm.
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OLN-93 cells, the expression of MBP isoforms during early rat brain de-
velopment was compared to the expression of MBP isoforms in OLN-93
lysates. As shown in Fig. 4C, prominent expression of exon-II-containing
MBP isoforms with the same molecular masses as present in OLN-93
cellswas apparent in the embryonic stage (E18). These variants, howev-
er, readily disappeared within the early phase (i.e., within 72–96 h) of
the postnatal stage. Furthermore, the 16-kDa e-MBP band was also de-
tected in prenatal rat brain (Fig. 4C, arrow) and in primary rat oligoden-
drocytes at different maturation stages after initiating differentiation
(Fig. 4D, arrow). Interestingly, the 16-kDa e-MBP wasmore prominent-
ly expressed early (i.e., 3 days) after initiating differentiation, than at
later stages (7 and 10 days), whereas the exon-II speciﬁcity of this iso-
form was conﬁrmed with an anti-exon-II antibody (data not shown).
As indicated above, given that e-MBP contains exon-II, we therefore
next examined whether e-MBP and postnatal exon-II-positive MBP
isoforms have similar subcellular localizations. Immunocytochemical
studies revealed that e-MBP, similarly as the postnatal exon-II-positive
21.5-kDa MBP–RFP in OLN-93 cells, and postnatal exon-II MBP
isoforms in oligodendrocytes (not shown; [12,26,42]), displayed a
nucleocytoplasmic distribution pattern (Fig. 4E). Remarkably, cytoplas-
mic expression appeared as dots, consistent with a previous study [29].
Unfortunately, the anti-exon-II antibody is not suitable for immunocy-
tochemistry. Since the 16-kDa e-MBP represents by far the major MBP
fraction (Fig. 4A), we assume that the distinctive localization in either
the cytoplasm, nucleus, or both reﬂects the distribution of this particu-
lar isoform.
3.4. The localization of embryonic MBP correlates with cell proliferation
As previously shown in HeLa cells, cell density is one of the factors
that affects the intracellular distribution of postnatal exon-II-positive
MBP isoforms. Thus, when cells are plated at high cell density, the
percentage of nuclear MBP localization decreases as compared to low-
density cultures [12]. To determine whether e-MBP behaves similarly
as classical postnatal exon-II positive MBP isoforms [12], OLN-93 cells
were plated at a low and high cell density and subsequently cultured
for 3 days. At low density, approx. 50% of the cells showed a nuclear
localization for e-MBP, whereas in high-density cultures, e-MBP was
largely excluded from the nucleus, i.e., the percentage of cells with
nuclear e-MBP was reduced to approx. 15% (Fig. 5A, B, LD and HD, re-
spectively). Importantly, it should be noted that the overall expression
levels of e-MBP were not affected by cell density (Fig. 5C), suggesting
a genuine shift in intracellular e-MBP distribution.
To obtain further support for such a cell density dependent shift,
subcellular fractionation was carried out. To this end, three subcellular
fractions, i.e., a nuclear, membrane, and cytoplasmic fraction were iso-
lated from equal volumes of cell lysates obtained from low- and high-
density cultures. Consistent with its physical nature as a peripheral
membrane-bound protein, e-MBP was present in either the nuclear or
membrane fraction, whereas it was completely absent from the cyto-
plasmic fraction (Fig. 5D). To assess the purity of the different fractions,
NCAM 140was used amembranemarker, and histone 3 as amarker for
the nuclear fraction. Thus, after appropriate corrections for fraction pu-
rity, the nucleus to membrane ratio was consistently decreased in high-
density cultures (Fig. 5D), in agreement with the immunocytochemical
data (Fig. 5A, B). Together, these data indicate that cell density does not
alter the overall expression levels of e-MBP, but does affect translo-
cation of the protein from the nucleus to the cytoplasm. Previous
studies have provided evidence that cell density controls cell prolif-
eration, i.e., cells proliferate faster in low-density cultures than in
high-density cultures [43,44]. We therefore next examined whether,
as for 21.5-kDa MBP, there might be a direct link between cell prolifer-
ation and e-MBP translocation.
To examine OLN-93 cell proliferation as a function of cell density, a
BrdU incorporation assay was performed. As shown in Fig. 5F,proliferation was slightly, but signiﬁcantly, decreased at high cell densi-
ty relative to low cell density. Concomitantly, the majority of the prolif-
erating cells also showed a nuclear staining for e-MBP at low-density
cultures (Fig. 5E, G). In contrast, at high cell density, only a minor frac-
tion of the proliferating cells harbor nuclear e-MBP, suggesting an
uncoupling of cell proliferation and nuclear e-MBP expression upon
cell–cell contact. Of note, e-MBPmight regulate rather than trigger pro-
liferation, as 55% of the cells that had nuclear e-MBP at high cell density
cultures did incorporate BrdU during an 8 h pulse, whereas only 12% of
nuclear e-MBP expressing OLN-93 cells proliferated in low-density cul-
tures (Fig. 5H).
To assess more convincingly a direct correlation between prolifera-
tion and nuclear e-MBP expression, we next examined e-MBP localiza-
tion in low-density cultures in two conditions that inhibit proliferation,
i.e., upon serum deprivation, or in the presence of the CDK inhibitor
roscovitine (Fig. 6). Concomitant with a 50% block in proliferation in
either condition, the percentage of nuclear localization of e-MBP de-
creased by approx. 50% (Fig. 6A, C). Of note, serum deprivation did not
affect the e-MBP expression levels (data not shown). Interestingly,
upon re-establishing proliferating conditions (Fig. 6B), i.e., upon addi-
tion of serum-containing medium or removal of the CDK inhibitor
followed by addition of serum-containing medium, respectively, the
level of nuclear e-MBP localization returned to the level at starting
conditions.
3.5. shRNA knockdown of MBP in OLN-93 cells decreases proliferation
To determine a direct link between e-MBP and proliferation, a
lentiviral-mediated shRNA knockdown of MBP expression in OLN-93
cells was performed. Transduction of OLN-93 cells with shRNA directed
against the interface of exon-III and exon-IV, two exons present in
all MBP isoforms, showed at an approx. 50% efﬁciency a signiﬁcant
reduction of e-MBP expression compared to non-transduced cells, as
examined byWestern blotting (Fig. 7A, approx. 40% reduction) and im-
munocytochemistry (Fig. 7B). To assess proliferation, a BrdU incorpora-
tion assay was combined with GFP immunocytochemistry (Fig. 7C).
Proliferation was markedly decreased in GFP-positive cells, i.e., MBP
shRNA-containing cells, as compared to GFP-negative cells on the
same coverslip (Fig. 7D). Notably, due to the ﬁxation procedure, GFP
appeared in the nucleus [45]. Taken together, these data indicate that
e-MBP, like postnatal 21.5-kDa MBP, presumably plays a regulatory
role in proliferation,which is correlatedwith its presence in the nucleus.
Given its ubiquitous presence in both oligodendroglial cells and non-
myelinated tissue [17], we subsequently wondered whether e-MBP
may exert its effect beyond that ofmyelinating cells only, thus reﬂecting
a general role as regulator of cell proliferation.
3.6. e-MBP is also a regulator of proliferation in non-myelinating cell lines
Whereas the postnatal isoforms are exclusively expressed in
myelinating cells, e-MBP is present at the protein level in various
other tissues during embryonic development, including the liver, thy-
mus, and spleen [17]. However, since the function of e-MBP in other tis-
sues has not been clariﬁed so far, we next exploredwhether e-MBPmay
also act as a regulator of proliferation in non-myelinating cells. To this
end, three different cell lines, i.e., HEK293 cells, a cell line originally de-
rived from human embryonic kidney, HeLa cells, a human immortal cell
line derived from cervical cancer, and HepG2 cells, a human hepatocel-
lular liver carcinoma cell line, were examined by Western blot analysis
for e-MBP expression. As shown in Fig. 7E, all examined cell lines ex-
press e-MBP, and similarly as observed inOLN-93 cells, e-MBPdisplayed
in all cell lines a nucleocytoplasmic distribution pattern (Fig. 7F). Trans-
duction of HeLa cells with MBP shRNA (approx. 90% efﬁciency) led to a
major reduction in e-MBP expression (Fig. 7G, approx. 90% reduction),
with a concomitant decrease in cell proliferation of 50% (Fig. 7H, I). Con-
sistently, cell proliferation was similarly reduced upon downregulation
Fig. 5. Cell density dependent localization of e-MBP correlateswith cell proliferation. OLN-93 cells were plated at a low density (LD, 2000 cells per well) or high density (HD, 8000 cells per
well), and cultured for 3 days. Representative blots and images of at least three independent experiments are shown. (A, B) Cells were ﬁxed and stained for MBP (A). For each condition,
the percentage of nuclear e-MBP expression of total DRAQ5-positive cells was determined (B). Note that nuclear e-MBP localization decreased in high cell density cultures. Scale bar is
20 μm. (C) Equal amounts of protein (50 μg) obtained from total OLN-93 cell lysates were subjected toWestern blot analysis using the anti-MBP polyclonal antibody. The e-MBP expres-
sion levels were quantiﬁed relative to the expression of the housekeeping gene β-actin. Note that e-MBP expression levels are similar at both cell densities. (D) OLN-93 cell lysates were
subjected to subcellular fractionation followed byWestern blot analysis forMBP (pAb), NCAM 140 (membranemarker) and H3 (histone 3, nuclearmarker). Equal volumes of nuclear (N),
membrane (M), and cytoplasmic (C) fractions were loaded. For each condition, the nucleus to membrane ratio (N/M) of e-MBP was determined taking fraction purity into account.
Relative ratio of high-density to low-density cultures is shown, which was set to 1 in each experiment. Note that the nucleus to membrane ratio for e-MBP is decreased in high-density
cultures. (E–H) Cell proliferationwas determined using a BrdU incorporation assay. The percentage proliferative cells, i.e., BrdU-positive, of total, i.e., DRAQ5-positive cells was determined
(F). In panels (E, G) and (H), a BrdU incorporation assay was combined with e-MBP immunocytochemistry. Scale bar in panel E is 20 μM. The percentage of nuclear e-MBP localization in
BrdU-positive cells is shown in panel (G) and the percentage of BrdU-positive cells of the nuclear e-MBP containing cells is shown in panel (H). Note that OLN-93 cells proliferatemore in
low-density cultures,whereas the percentage of proliferating cellswith nuclear e-MBP signal is higher in low-density cultures. Statistical analysis in (B–D) and (F–H)was performedusing
GraphPad Prism 5 [(one-sample) t-test, *p b 0.05, ***p b 0.001]. Values shown in (B–D) and (F–H) are means + SD of at least three independent experiments.
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to a lesser extent than in OLN-93 and HeLa cells (Fig. 7). Given that at
low-density cultures OLN-93 and HeLa cells grow as single cells
(Fig. 7), and HepG2 and HEK293 cells in cell clusters with many cell–
cell contacts (Supplementary Fig. 4), a partial uncoupling of e-MBPand cell proliferation, for the latter two cell lines could be envisioned,
as observed upon cell-cell contact in OLN-93 cells (Fig. 5). Of note, a
marked downregulation of e-MBP levels was only observed at least
11 days after transduction with shRNA against MBP, indicating that
the turnover of e-MBP is very low and likely cell type dependent.
Fig. 6. Localization of e-MBP changes upon mitogenic modulation. OLN-93 cells plated at an initial density of 2000 cells per well were cultured for 2 days, and either ﬁxed (control), or
treated with roscovitine (20 μM), or cultured in serum-free (SF) culture medium. After 1 day, cells were ﬁxed or allowed to recover in normal culture medium supplemented with
10% FCS (Recovery) for 1 day. (A) Localization of e-MBP at the indicated conditions, as determined by immunocytochemistry. Representative images of three independent experiments
are shown. Scale bar is 20 μm. (B) Cell proliferation as determinedwith a BrdU incorporation assay. Note that cell proliferation is blockedby 50%when cultured in serum-free (SF)medium
or upon treatment with roscovitine, whereas cell proliferation is recovered upon (re)-addition of 10% FCS. (C) Quantitative analysis of (A) at the indicated conditions (the percentage of
cells with nuclear e-MBP expression relative to total, DRAQ5-positive cells) was examined. Note that upon inhibition of cell proliferation, e-MBP preferentially localizes to the cytoplasm,
whereas in control and during recovery, i.e., at proliferating conditions, e-MBP preferentially localizes to the nucleus. The graphs were plotted as mean + SD and statistical analysis was
performed using GraphPad Prism 5 (one-way ANOVA followed by the Newman–Keuls posttest *p b 0.05, **p b 0.01, ***p b 0.001).
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myelinating cells, e-MBP is also abundantly expressed in embryonic-
and cancer-derived cell lines, and appears to act as a general regulator
of cell proliferation.
4. Discussion
In the present study, we demonstrate that exon-II-containing em-
bryonic 16-kDa MBP and the postnatal 21.5-kDa MBP shuttle between
the nucleus and the cytoplasm, and that their nuclear localization regu-
lates cell proliferation. Thus, in the absence of amitogenic signal or upon
CDK inhibition, the exon-II-containing MBP isoforms translocate from
the nucleus to the cytoplasm, and re-appear in the nucleus whenproliferation is re-induced. Furthermore, knockdown of MBP via
shRNA interference signiﬁcantly decreased proliferation. Therefore,
exon-II-containing MBPs might be prominent regulators of oligoden-
drocyte proliferation. In this context, given the increased expression of
postnatal exon-II-positive MBP isoforms at the onset of remyelination
[16,46], it is tempting to suggest that these isoforms might function in
a similar manner as important mediators in the early regulation of my-
elin biogenesis.
Classical MBP isoforms are generally considered as important
markers for differentiated oligodendrocytes because of their localization
and functioning in themyelin sheath. However, these differentMBP iso-
forms are generated upon alternative splicing of a single MBP transcript
of three of its seven exons, i.e., exons II, V, and VI. Speciﬁcally, the
Fig. 7. shRNA knockdown ofMBP signiﬁcantly decreases cell proliferation. (A–D) OLN-93 cells were untreated (ctrl), or transducedwith shRNA directed against all isoforms ofMBP (MBP
↓), and analyzed 12 days after transduction. (A) Equal amounts of protein (20 μg) were subjected to Western blot analysis using the anti-MBP polyclonal antibody. Note the signiﬁcant
reduction (40%) of e-MBP protein upon transduction with MBP shRNA. (B) Cells were ﬁxed and co-stained for MBP and GFP. The expression of GFP conﬁrms the shRNA lentiviral trans-
duction. A representative confocal image of three independent experiments is shown. Scale bar is 20 μm. Note that e-MBP is absent in GFP-positive cells. (C–D) Cell proliferation was de-
termined using a BrdU incorporation assay combinedwith GFP immunocytochemistry (C). Scale bar is 20 μm. The percentage of proliferative cells, i.e., BrdU-positive (arrowhead), of total
GFP-positive (arrow) andGFP-negative cells (ctrl)was determined (D). Note that OLN-93 cells that contain shRNA againstMBP, i.e., GFP-positive cells, proliferate less. Statistical analysis in
(D)wasperformedusingGraphPad Prism 5 (t-test, *p b 0.05). Values shown inpanel (D) aremeans + SDof at least three independent experiments. (E) Equal amounts of protein (50 μg)
were subjected toWestern blot analysis using the anti-MBP polyclonal antibody. Note the presence of e-MBP in the examined cell lines (arrow). (F) The indicated cell lines were ﬁxed at
24 h in culture and stainedwith anti-MBPmonoclonal antibody. A representative confocal image of three independent experiments is shown. Note that MBP localizes both to the nucleus
(bright ﬂuorescence) and to the cytoplasm (punctate appearance) in the examined cell lines. Scale bar is 20 μm. (G–I) HeLa cells were untreated (ctrl), or transducedwith shRNA directed
against all isoforms ofMBP (MBP↓), and analyzed 12 days after transduction. (G) Equal amounts of protein (70 μg)were subjected toWestern blot analysis using the anti-MBP polyclonal
antibody. Note the signiﬁcant reduction (90%) of e-MBP protein upon transduction with MBP shRNA. (H, I) Cell proliferation was determined using a BrdU incorporation assay combined
with GFP immunocytochemistry (H). Scale bar is 20 μm. The percentage of proliferative cells, i.e., BrdU-positive, of total cells was determined (I). Note that HeLa cells that contain shRNA
against MBP, i.e., GFP-positive cells, proliferate less. Statistical analysis in panel I was performed using GraphPad Prism 5 (t-test, *p b 0.05). Values shown in panel I are means + SD of at
least three independent experiments.
528 H. Ozgen et al. / Biochimica et Biophysica Acta 1843 (2014) 517–530expression of exon-V-negativeMBP isoforms is apparent already at em-
bryonic development, and their subsequent (dis)appearance at the
postnatal stage is developmentally regulated [16,17], emphasizing
their distinct roles throughout the development of myelinating cells.
Here, we show that the oligodendrocyte progenitor cell line, OLN-93,
expresses an exon-II-positive embryonic 16-kDa MBP isoform, which
is localized to the nucleus and cytoplasm. The subcellular localization
of e-MBP is regulated by cell–cell interactions, i.e., e-MBP redistributedto the cytoplasm at high cell density, like classical postnatal exon-II-
containing MBP isoforms [12,24]. As observed for many cell types, and
consistent with a density-dependent diminution of the proliferation of
OPCs [47,48], OLN-93 cell proliferation was markedly decreased upon
cell–cell contact. At low cell density, the majority of the proliferating
cells showed a nuclear localization of e-MBP, suggesting a role for nucle-
us localized e-MBP in cell proliferation. However, in the absence of ami-
togenic signal, e-MBP translocated from the nucleus to the cytoplasm,
529H. Ozgen et al. / Biochimica et Biophysica Acta 1843 (2014) 517–530yet re-appeared in the nucleus when proliferation was re-induced. No-
tably, in the low-density cultures, the majority of OLN-93 cells that had
nuclear e-MBP did not proliferate during an 8 h BrdU pulse, suggesting
that nuclear e-MBP as such regulates rather than triggers proliferation.
Indeed, at high cell density, OLN-93 cells with e-MBP localized in the cy-
toplasm were still remarkably proliferative, whereas cells in these cul-
tures with fewer cell–cell contacts showed nuclear e-MBP localization
and proliferated. The latter phenomenon presumably reﬂects the same
process as observed at low cell density. In addition, knock-down of
MBP gene expression via RNA interference conﬁrmed a role for e-MBP
in proliferation at low cell density. Hence, our data indicate that
nuclear-localized e-MBP likely regulates cell proliferation uponmitogenic
activation, i.e., in the absence of cell–cell contact, whereas upon cell–cell
interactions, an e-MBP independent proliferation signaling pathway
might be activated [49].
Here, we also demonstrate that the expression and function of
e-MBP is not restricted to cells of the oligodendrocyte lineage.
Thus, e-MBP is also expressed in several non-CNS cell lines showing
a nucleocytoplasmic distribution pattern, while its downregulation
by shRNA resulted in a decrease of cell proliferation. Therefore, e-MBP
appears to play a role in proliferation in a variety of tissues during em-
bryonic and neonatal development. In addition, given the expression of
e-MBP in cancer-derived cell lines, a role in the proliferation of cancer
cells might be envisioned. However, and similar to OLN-93 cells, a par-
tial uncoupling of e-MBP and cell proliferationwas observed in cell lines
withmany cell–cell contacts. These ﬁndings also imply that e-MBP does
not require oligodendrocyte speciﬁc factors for regulating proliferation.
Although themechanism bywhich e-MBP regulates cell proliferation is
not known at this time, our preliminary work suggests a direct interac-
tion between e-MBP and the well-known and ubiquitous CDK inhibitor
p27 under proliferating conditions, whereas live-cell imaging studies
demonstrated that e-MBP exits the nucleus before p27 (our unpub-
lished observations).
During postnatal development, the level of expression of MBP
isoforms is markedly modulated in oligodendrocytes and not in the
other tissues. The appearance of postnatal MBP isoforms is regulated
at the transcription level via a coordinated action of various
oligodendrocyte-speciﬁc transcription factors [50,51]. Thus, the level
of e-MBP decreases rapidly (Fig. 4), while postnatal exon-II-containing
MBP isoforms peak during early development [14]. In contrast, the
exon-II-negative postnatal isoforms are primarily expressed at later
stages of oligodendrocyte maturation [2,11,12,14,16]. As for exon-II-
containing e-MBP, the nuclear localization of postnatal exon-II-
containing 21.5-kDa MBP–RFP correlated with increased proliferation.
Quantitative FRAP analysis revealed that the nuclear import rate of
21.5-kDa MBP–RFP decreased upon serum deprivation, whereas
concomitantly, the nuclear export rate increased. Replenishment of
serum, i.e., activating proliferation, restored the nuclear import rate to
a similar level as observed before serum deprivation. Interestingly, re-
establishment of the nuclear export rate displayed a lag phase, which
might suggest thatmodiﬁcations of 21.5-kDaMBP–RFPmight be essen-
tial for its nuclear export. Indeed, phosphorylation of many nuclear-
localized proteins, e.g., p27, has been associated with their nuclear ex-
port [33,52], as has also been suggested for 21.5-kDa MBP export [24].
NuclearMBP isoforms do carry two non-traditional PY-nuclear localiza-
tion signals within the exon-II sequence [53], whereas they do not
possess a classical nuclear export signal. The nuclear export of MBP
apparently requires another protein, since our live-cell imaging data
and FRAP analysis revealed that the CRM1 nuclear export inhibitor,
LMB, prevented nuclear export of 21.5-kDa MBP–RFP.
Taken together, in contrast to exon-II devoid MBP isoforms that act
as a molecular sieve and have a role in myelin compaction [2,19,22],
postnatal and embryonic exon-II-containing MBP isoforms likely play
a regulatory role in oligodendrocyte proliferation. The exact role of 26
amino acids containing exon-II in this process remains to be deter-
mined, particularly since very recently golli MBPs, which lack exon-II[54] may also show a nuclear localization pattern, and have been
proposed to play a role in oligodendrocyte proliferation during
remyelination [55]. Further studies are needed to reveal the underlying
mechanism(s) as to how e-MBP and postnatal exon-II-positive MBP
modulate proliferation, and whether these mechanisms are similar. As
shown in the present manuscript in OLN-93 cells, and in a previous
study in N19 cells [27], the proliferation of both transfected and
untransfected cells was increased, while a nuclear localization of
21.5-kDa MBP–RFP was required. Therefore, expression of exon-II-
containing MBPs highly likely increased cell proliferation via a diffus-
ible factor, and although the identity of this diffusible factor is currently
unknown, the expression and/or secretion might be regulated by the
presence of exon-II-containing MBP in the nucleus or its absence in
the cytoplasm. Given that e-MBP is functionally expressed in other tis-
sues [17,41] and in a variety of cell lines (as we have shown here), an
understanding of the mechanism(s) might also provide novel means
to control (ab)normal proliferation, as occurs in cancer.
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